Page 333 - Read Online

Yao et al. Hepatoma Res 2018;4:30 I http://dx.doi.org/10.20517/2394-5079.2018.32 Page 9 of 10

40. Mokkapati S, Niopek K, Huang L, Cunniff KJ, Ruteshouser EC, deCaestecker M, Finegold MJ, Huff V. β-Catenin activation in a novel
liver progenitor cell type is sufficient to cause hepatocellular carcinoma and hepatoblastoma. Cancer Res 2014;74:4515-25.
41. Guerrieri F, Belloni L, Pediconi N, Levrero M. Molecular mechanisms of HBV- associated hepatocarcinogenesis. Semin Liver Dis
2013;33:147-56.
42. Daud M, Rana MA, Husnain T, Ijaz B. Modulation of Wnt signaling pathway by hepatitis B virus. Arch Virol 2017;162:2937-47.
43. Monga SP. β-Catenin signaling and roles in liver homeostasis, injury, and tumorigenesis. Gastroenterology 2015;148:1294-310.
44. Park S, Lim J, Kim JR, Cho S. Inhibitory effects of resveratrol on hepatitis B virus X protein-induced hepatocellular carcinoma. J Vet Sci
2017;18:419-29.
45. Yen CJ, Ai YL, Tsai HW, Chan SH, Yen CS, Cheng KH, Lee YP, Kao CW, Wang YC, Chen YL, Lin CH, Liu T, Tsai HP, Wang JR, Su
IJ, Huang W. Hepatitis B virus surface gene pre-S2 mutant as a high-risk serum marker for hepatoma recurrence after curative hepatic
resection. Hepatology 2018; doi: 10.1002/hep.29790.
46. Gao Y, Feng J, Yang G, Zhang S, Liu Y, Bu Y, Sun M, Zhao M, Chen F, Zhang W, Ye L, Zhang X. Hepatitis B virus X protein-elevated
MSL2 modulates hepatitis B virus covalently closed circular DNA by inducing degradation of APOBEC3B to enhance hepatocarcinogenesis.
Hepatology 2017;66:1413-29.
47. Geng M, Xin X, Bi LQ, Zhou LT, Liu XH. Molecular mechanism of hepatitis B virus X protein function in hepatocarcinogenesis. World J
Gastroenterol 2015;21:10732-8.
48. Ashmawy AM, Elgeshy KM, Abdel Salam ET, Ghareeb M, Kobaisi MH, Amin HAA, Sharawy SK, Abdel Wahab AHA. Crosstalk
between liver-related microRNAs and Wnt/β-catenin pathway in hepatocellular carcinoma patients. Arab J Gastroenterol 2017;18:144-50.
49. Preziosi M, Poddar M, Singh S, Monga SP. Hepatocyte Wnts are dispensable during diethylnitrosamine and carbon tetrachloride-induced
injury and hepatocellular cancer. Gene Expr 2018; doi: 10.3727/105221618X15205148413587.
50. Han Y, Niu J, Wang D, Li Y. Hepatitis C virus protein interaction network analysis based on hepatocellular carcinoma. PLoS One
2016;11:e0153882.
51. Rogacki K, Kasprzak A, Stępiński A. Alterations of Wnt/β-catenin signaling pathway in hepatocellular carcinomas associated with hepatitis
C virus. Pol J Pathol 2015;66:9-21.
52. Wang W, Pan Q, Fuhler GM, Smits R, Peppelenbosch MP. Action and function of Wnt/β-catenin signaling in the progression from chronic
hepatitis C to hepato- cellular carcinoma. J Gastroenterol 2017;52:419-31.
53. Jiang XH, Xie YT, Cai YP, Ren J, Ma T. Effects of hepatitis C virus core protein and nonstructural protein 4B on the Wnt/β-catenin
pathway. BMC Microbiol 2017;17:124.
54. Liu J, Ding X, Tang J, Cao Y, Hu P, Zhou F, Shan X, Cai X, Chen Q, Ling N, Zhang B, Bi Y, Chen K, Ren H, Huang A, He TC, Tang N.
Enhancement of canonical Wnt/β-catenin signaling activity by HCV core protein promotes cell growth of hepatocellular carcinoma cells.
PLoS One 2011;6:e27496.
55. Liu J, Wang Z, Tang J, Tang R, Shan X, Zhang W, Chen Q, Zhou F, Chen K, Huang A, Tang N. Hepatitis C virus core protein activates
Wnt/β-catenin signaling through multiple regulation of upstream molecules in the SMMC-7721 cell line. Arch Virol 2011;156:1013-23.
56. Kasprzak A, Rogacki K, Adamek A, Sterzyńska K, Przybyszewska W, Seraszek-Jaros A, Helak-Łapaj C, Pyda P. Tissue expression of
β-catenin and E- and N-cadherins in chronic hepatitis C and hepatocellular carcinoma. Arch Med Sci 2017;13:1269-80.
57. Umer M, Qureshi SA, Hashmi ZY, Raza A, Ahmad J, Rahman M, Iqbal M. Promoter hypermethylation of Wnt pathway inhibitors in
hepatitis C virus - induced multistep hepatocarcinogenesis. Virol J 2014;11:117.
58. Liu Y, El-Serag HB, Jiao L, Lee J, Moore D, Franco LM, Tavakoli-Tabasi S, Tsavachidis S, Kuzniarek J, Ramsey DJ, White DL. WNT
signaling pathway gene polymorphisms and risk of hepatic fibrosis and inflammation in HCV-infected patients. PLoS One 2013;8:e84407.
59. Quan H, Zhou F, Nie D, Chen Q, Cai X, Shan X, Zhou Z, Chen K, Huang A, Li S, Tang N. Hepatitis C virus core protein epigenetically
silences SFRP1 and enhances HCC aggressiveness by inducing epithelial-mesenchymal transition. Oncogene 2014;33:2826-35.
60. Ueda T, Honda M, Horimoto K, Aburatani S, Saito S, Yamashita T, Sakai Y, Nakamura M, Takatori H, Sunagozaka H, Kaneko S.
Gene expression profiling of hepatitis B- and hepatitis C-related hepatocellular carcinoma using graphical Gaussian modeling. Genomics
2013;101:238-48.
61. Lu C, He Y, Duan J, Yang Y, Zhong C, Zhang J, Liao W, Huang X, Zhu R, Li M. Expression of Wnt3a in hepatocellular carcinoma and its
effects on cell cycle and metastasis. Int J Oncol 2017;51:1135-45.
62. Zhang C, Li C, Chen X, Zhou Y, Yin B, Ni R, Zhang Y, Liu J. Overexpression of dishevelled 2 is involved in tumor metastasis and is
associated with poor prognosis in hepatocellular carcinoma. Clin Transl Oncol 2017;19:1507-17.
63. Sakabe T, Azumi J, Umekita Y, Toriguchi K, Hatano E, Hirooka Y, Shiota G. Expression of cancer stem cell-associated DKK1 mRNA
serves as prognostic marker for hepatocellular carcinoma. Anticancer Res 2017;37:4881-8.
64. Davaadorj M, Imura S, Saito YU, Morine Y, Ikemoto T, Yamada S, Takasu C, Hiroki T, Yoshikawa M, Shimada M. Loss of SFRP1
expression is associated with poor prognosis in hepatocellular carcinoma. Anticancer Res 2016;36:659-64.
65. Wang L, Yao M, Fang M, Zheng WJ, Dong ZZ, Pan LH, Zhang HJ, Yao DF. Expression of hepatic Wnt5a and its cliniopathological
features in patients with hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int 2018;17:227-32.
66. Wang L, Pan LH, Yao M, Zheng WJ, Fang M, Qiu LW, Dong ZZ, Yao DF. Clinical values of Wnt3a as a novel biomarker in diagnosis and
prognosis of hepatocellular carcinoma. Zhonghua Yi Xue Za Zhi 2016;96:3554-8. (in Chinese)
67. Naboulsi W, Megger DA, Bracht T, Kohl M, Turewicz M, Eisenacher M, Voss DM, Schlaak JF, Hoffmann AC, Weber F, Baba HA, Meyer
HE, Sitek B. Quantitative tissue proteomics analysis reveals versican as potential biomarker for early-stage hepatocellular carcinoma. J
Proteome Res 2016;15:38-47.
68. Su YH, Lin SY, Song W, Jain S. DNA markers in molecular diagnostics for hepatocellular carcinoma. Expert Rev Mol Diagn